Scarpato Kristen R, Tyson Mark D, Clark Peter E
Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Curr Opin Oncol. 2016 May;28(3):210-5. doi: 10.1097/CCO.0000000000000278.
This article reviews the natural biology of noninvasive bladder cancer and its management strategies while summarizing the most recent advances in the field.
Nonmuscle invasive bladder cancer (NMIBC) has a tendency to recur and progress. Risk stratification has helped triage patients but improved tools, including biomarkers, are still needed. Enhanced endoscopy with photodynamic imaging, narrow band imaging, optical coherence tomography and confocal laser endomicroscopy show promise for diagnosis, risk stratification and disease monitoring. Attempts at better treatment, especially in refractory high-risk cases, include the addition of intravesical hyperthermia, combination and sequential therapy with existing agents and the use of novel agents such as mycobacterial cell wall extract. New data are emerging regarding the potential role of active surveillance in low-risk patients.
NMIBC represents a variety of disease states and continues to pose management challenges. As our understanding of tumor biology improves and technology advances, achieving better outcomes through individualized care may be possible.
本文回顾了非侵袭性膀胱癌的自然生物学特性及其管理策略,同时总结了该领域的最新进展。
非肌层浸润性膀胱癌(NMIBC)有复发和进展的倾向。风险分层有助于对患者进行分类,但仍需要包括生物标志物在内的改进工具。增强型内镜检查,如光动力成像、窄带成像、光学相干断层扫描和共聚焦激光显微内镜检查,在诊断、风险分层和疾病监测方面显示出前景。更好治疗的尝试,特别是在难治性高危病例中,包括增加膀胱内热疗、与现有药物联合及序贯治疗,以及使用新型药物,如分枝杆菌细胞壁提取物。关于主动监测在低风险患者中的潜在作用,新的数据正在出现。
NMIBC代表多种疾病状态,仍然带来管理挑战。随着我们对肿瘤生物学的理解不断提高和技术进步,通过个体化治疗实现更好的治疗效果或许是可能的。